% Generated by roxygen2: do not edit by hand
% Please edit documentation in R/data.R
\docType{data}
\name{cm214_pfs}
\alias{cm214_pfs}
\title{Sample Reconstructed Data of CheckMate214 Study}
\format{
A dataset containing 3 columns:
\describe{
  \item{time}{the time-to-event variable (the time unit is month)}
  \item{status}{the event indicator (1=event, 0=censor)}
  \item{arm}{the treatment indicator (1=treatment, 0=control)}
}
}
\source{
Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma.
New England Journal of Medicine. 2018;378(14):1277â€“1290. <doi:10.1056/NEJMoa1712126>
Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12(1):9. <doi:10.1186/1471-2288-12-9>
}
\usage{
data(cm214_pfs)
}
\description{
The progression-free survival data reconstructed from the publication of the CheckMate214 study.
}
\details{
This is a reconstructed patient-level data from the results reported by Motzer et al.(2018) <doi:10.1056/NEJMoa1712126>.
The data consists of 847 patients with previously untreated clear-cell advanced renal-cell carcinoma; 425 for the nivolumab plus ipilimumab group (treatment) and 422 for the sunitinib group (control).
}
\keyword{datasets}
